EPISODE · Dec 5, 2022 · 49 MIN
Eye Believe 2022: D2T1 Ocular Melanoma Met’s Explained
from The Eye Believe Podcast · host A Cure In Sight
Join Dr. Justin Moser and Dr. Meredith McKean, together with Dr. Sanger to discuss navigating an ocular melanoma mets diagnosis. Dr. Moser is a Medical Oncologist who specializes in phase 1 clinical trials, drug development, and cutaneous malignancies. He leads the Melanoma program at HonorHealth Research Institute, and runs one of the only programs dedicated to uveal melanoma in Arizona. Dr. Meredith McKean received her bachelor's degree from Iowa State University, where the promising athlete ran cross-country and track. McKean completed her fellowship in Hematology-Oncology at the University of Texas MD Anderson Cancer Center. She now serves as the associate director for the Melanoma and Skin Cancer Research Program at the Sarah Cannon Research Institute of Tennessee Oncology. Maureen Sanger, PhD is a psychologist with Tennessee Oncology providing counseling to cancer patients and survivors. She received her doctorate in clinical psychology from Vanderbilt University and trained at MD Anderson Cancer Center. Prior to joining Tennessee Oncology she was an Assistant Professor of Pediatrics at Vanderbilt University Medical Center where she worked with the cancer and sickle cell disease programs.
Embed this episode
What this episode covers
Join A Cure in Sight for the Eye Believe 2022 Survivorship seminar, hosted in Nashville, TN by Dr. Reichstein with Tennessee Retina. This podcast and this Eye Believe Session are possible because of our presenting sponsor, Castle Biosciences. Thank you to all our sponsors, Immunocore, Delcath, TriSalus, and Aura, Foghorn Therapeutics, and Replimune, without whom this event wouldn’t be possible.
NOW PLAYING
Eye Believe 2022: D2T1 Ocular Melanoma Met’s Explained
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.